Inclusion Criteria:

- Age: 18 to 75

- Histologically or cytologically documented gastric adenocarcinoma and
esophagus-gastro adenocarcinoma of metastatic or advanced stages with/without
measurable tumor according to RECIST standard

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

- Patients who are expected to live at least 3 months

- No prior systemic chemotherapy with advanced stereo- tumor before the
recruitment(recidivist/ metastatic without perioperative chemotherapy at least 6m)

- No Previous anaphylactic reaction to hormone

- Obtaining informed consent

- Patients may comply with the study protocol

- Laboratory tests: Absolute neutrophil count (ANC) ≥2,000/mm³, Platelet count
≥100,000/mm³, Hemoglobin ≥9.0 g/dL, Serum creatinine≤1.5 x the institutional upper
limit of normal (ULN), Creatinine clearance≥50ml/min，Total bilirubin≤1.5 x the
institutional upper limit of normal (ULN), Alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) ≤1.5 x ULN. In the case of known liver metastasis,
ALT and AST（SGOT） ≤1.5 x ULN.

Exclusion Criteria:

- Active uncontrolled central nervous system metastasis

- No adequate organ function or known disease :

- myocardial infarction

- active heart disease

- neuropathy or mental diseases including dementia or epilepsy

- blind、deaf、dumb or extremity disability

- known infection

- active diffuse intravascular coagulation

- known infection with hepatitis virus

- Pregnant or nursing,fertile patients would not use effective contraception during
study treatment

- Prior clinically significant gastrointestinal tract disease , that would influence
obviously capecitabine to absorb,including the ability to swallow by the attending
physician

- No other active malignancies except that in complete remission with squamous cell
carcinoma in situ of the cervix or anus, completely resected basal cell carcinoma, or
no recrudescence for at least 2 year from the time a response was first documented

- Having other study medication within 4w

- Having radiation therapy or operation within 4w

- Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation
therapy) (except alopecie and hemoglobin)

- Peripheral nerve disease ≥ 2

- Previous anaphylactic reaction to Capecitabine and Paclitaxel or diluents bases

- Absence of dihydropyrimidine dehydrogenase

- Patients not suitable determined by the attending physician.